What is Strata Skin Sciences Inc's earnings per share (EPS)?

Strata Skin Sciences Inc (SSKN) reported diluted earnings per share of -$1.35 for fiscal year 2025. This represents a 49.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Strata Skin Sciences Inc Financials

SSKN

FY2025 annual

Revenue $30.7M -8.5% YoY

Net Income -$6.3M +37.9% YoY

EPS (Diluted) -$1.35 +49.1% YoY

Free Cash Flow -$4.3M -194.3% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 26, 2026 Currency USD FYE December

Strata Skin Sciences Inc (SSKN) reported $30.7M in revenue for fiscal year 2025, down 8.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SSKN FY2025 2026-08-15

Profitability improved faster than sales as STRATA cut operating drag, but short-term obligations now dominate the balance sheet.

Despite lower FY2025 revenue, operating loss narrowed from -$9.3M to -$4.7M. With gross margin still near 58.0%, that improvement points to cost discipline below gross profit rather than a richer sales mix, showing the main earnings lever is overhead control more than volume growth.

FY2025 net loss of -$6.3M turned into operating cash flow of -$2.8M because depreciation and amortization remained sizable, so part of the reported loss was non-cash and the income statement looked worse than the immediate cash drain. But after $1.5M of capital spending, free cash flow stayed negative at -$4.3M, meaning the business still relied on external financing instead of internally generated cash.

The balance sheet became short-term heavy: long-term debt fell to $0, but current liabilities climbed to $26.7M. That is a meaningful shift from earlier years, and liquidity is tighter than the zero-debt headline suggests because cash of $7.9M sits against a current ratio of 0.6x, so the remaining pressure is about near-term obligations rather than long-dated borrowing.

Financial Health Signals

Financial health score not available

Strata Skin Sciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Neutral

5/9

Strata Skin Sciences Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Strata Skin Sciences Inc reported a net loss of $6.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Strata Skin Sciences Inc reported an operating loss of $4.7M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$30.7M

YoY-8.5%

5Y CAGR+5.9%

10Y CAGR+5.2%

Strata Skin Sciences Inc generated $30.7M in revenue in fiscal year 2025. This represents a decrease of 8.5% from the prior year.

EBITDA

-$577K

YoY+86.5%

Strata Skin Sciences Inc's EBITDA was -$577K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 86.5% from the prior year.

Net Income

-$6.3M

YoY+37.9%

Strata Skin Sciences Inc reported -$6.3M in net income in fiscal year 2025. This represents an increase of 37.9% from the prior year.

EPS (Diluted)

-$1.35

YoY+49.1%

Strata Skin Sciences Inc earned -$1.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 49.1% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.3M

YoY-194.3%

Strata Skin Sciences Inc recorded an outflow of $4.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 194.3% from the prior year.

Cash & Debt

$7.9M

YoY+9.0%

5Y CAGR-5.7%

10Y CAGR+9.1%

Strata Skin Sciences Inc held $7.9M in cash against $0 in long-term debt as of fiscal year 2025, with $26.7M of liabilities due within a year.

Shares Outstanding

YoY+41.2%

Strata Skin Sciences Inc had 6M shares outstanding in fiscal year 2025. This represents an increase of 41.2% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

58.3%

YoY+1.0pp

5Y CAGR-3.0pp

10Y CAGR+32.4pp

Strata Skin Sciences Inc's gross margin was 58.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.

Operating Margin

-15.3%

YoY+12.3pp

5Y CAGR+2.3pp

10Y CAGR+73.8pp

Strata Skin Sciences Inc's operating margin was -15.3% in fiscal year 2025, reflecting core business profitability. This is up 12.3 percentage points from the prior year.

Net Margin

-20.4%

YoY+9.7pp

5Y CAGR-1.3pp

Strata Skin Sciences Inc's net profit margin was -20.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.7 percentage points from the prior year.

Return on Equity

-215.3%

YoY-12.4pp

5Y CAGR-198.3pp

10Y CAGR-60.2pp

Strata Skin Sciences Inc's ROE was -215.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$421K

YoY-52.3%

5Y CAGR-19.9%

10Y CAGR-14.6%

Strata Skin Sciences Inc invested $421K in research and development in fiscal year 2025. This represents a decrease of 52.3% from the prior year.

Capital Expenditures

$1.5M

YoY-10.3%

5Y CAGR-7.4%

Strata Skin Sciences Inc invested $1.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 10.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

SSKN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SSKN quarterly income statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$30.7M-8.5%	$33.6M+0.6%	$33.4M-7.8%	$36.2M+20.6%	$30.0M+29.8%	$23.1M-26.9%	$31.6M+5.8%	$29.9M-6.0%	$31.8M+3.4%	$30.7M+66.0%	$18.5M+1921.3%	$915K+70.7%	$536K+92.5%	$278K	N/A
Cost of Revenue	$12.8M-10.6%	$14.3M-3.7%	$14.9M+3.5%	$14.4M+42.1%	$10.1M+13.1%	$9.0M-20.9%	$11.3M-11.1%	$12.7M-2.0%	$13.0M+2.9%	$12.6M-7.9%	$13.7M+178.0%	$4.9M+13.7%	$4.3M+112.6%	$2.0M	N/A
Gross Profit	$17.9M-7.0%	$19.2M+4.1%	$18.5M-15.2%	$21.8M+9.7%	$19.9M+40.4%	$14.1M-30.3%	$20.3M+18.4%	$17.1M-8.8%	$18.8M+3.8%	$18.1M+278.4%	$4.8M+218.8%	-$4.0M-5.7%	-$3.8M-115.7%	-$1.8M	N/A
R&D Expenses	$421K-52.3%	$883K-33.0%	$1.3M+28.0%	$1.0M-28.2%	$1.4M+12.6%	$1.3M+27.1%	$1.0M-5.9%	$1.1M-37.8%	$1.7M-11.3%	$1.9M-4.9%	$2.0M+23.6%	$1.6M-56.6%	$3.8M-44.3%	$6.8M-29.7%	$9.7M
SG&A Expenses	$10.2M-6.5%	$10.9M+3.7%	$10.5M+4.2%	$10.1M+3.9%	$9.7M+23.0%	$7.9M-23.1%	$10.3M+16.9%	$8.8M+15.5%	$7.6M-0.4%	$7.6M-16.9%	$9.2M+192.8%	$3.1M-79.8%	$15.5M+9.6%	$14.2M+31.1%	$10.8M
Operating Income	-$4.7M+49.2%	-$9.3M-7.6%	-$8.6M-85.1%	-$4.6M-5.6%	-$4.4M-8.0%	-$4.1M-35.4%	-$3.0M+10.3%	-$3.4M-86.5%	-$1.8M+50.0%	-$3.6M+78.2%	-$16.5M+0.9%	-$16.6M+31.1%	-$24.1M-6.2%	-$22.7M-11.1%	-$20.5M
Interest Expense	$2.0M-7.0%	$2.1M+28.5%	$1.6M+77.1%	$926K+194.9%	$314K+48.8%	$211K-59.0%	$515K-54.9%	$1.1M-64.3%	$3.2M-34.8%	$4.9M-52.0%	$10.2M+330.0%	$2.4M+320.6%	$564K	N/A	N/A
Income Tax	$12K+107.1%	-$170K-84.8%	-$92K-246.0%	$63K+85.3%	$34K-87.6%	$275K+284.6%	-$149K+43.6%	-$264K-304.7%	$129K-49.4%	$255K+114.3%	$119K	$0	$0	N/A	N/A
Net Income	-$6.3M+37.9%	-$10.1M+6.9%	-$10.8M-95.2%	-$5.5M-105.1%	-$2.7M+38.7%	-$4.4M-16.4%	-$3.8M+6.0%	-$4.0M+81.3%	-$21.5M-545.1%	-$3.3M+86.6%	-$24.9M-76.4%	-$14.1M+45.5%	-$25.9M-14.4%	-$22.7M-11.2%	-$20.4M
EPS (Diluted)	-$1.35+49.1%	-$2.65	-$3.10	-$0.16	N/A	-$0.13-18.2%	-$0.11+26.7%	-$0.15	-$3.26	-$3.77	-$3.27	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$9.3M+34.1%	$6.9M-9.6%	$7.7M+12.5%	$6.8M-28.9%	$9.6M+8.9%	$8.8M+4.3%	$8.4M+24.9%	$6.8M
Cost of Revenue	$3.5M+29.3%	$2.7M-18.2%	$3.4M+6.1%	$3.2M-14.4%	$3.7M+5.3%	$3.5M+1.5%	$3.5M-5.9%	$3.7M
Gross Profit	$5.7M+37.3%	$4.2M-2.8%	$4.3M+18.1%	$3.6M-38.0%	$5.9M+11.2%	$5.3M+6.2%	$5.0M+61.6%	$3.1M
R&D Expenses	$67K-61.0%	$172K+100.0%	$86K-10.4%	$96K-52.0%	$200K-17.7%	$243K+22.1%	$199K-17.4%	$241K
SG&A Expenses	$2.3M-15.4%	$2.7M-11.0%	$3.0M+32.4%	$2.3M-4.3%	$2.4M-34.7%	$3.6M+64.4%	$2.2M-18.7%	$2.7M
Operating Income	$488K+141.6%	-$1.2M+49.2%	-$2.3M-35.5%	-$1.7M+60.2%	-$4.3M-167.0%	-$1.6M-235.8%	-$478K+83.4%	-$2.9M
Interest Expense	$484K-2.8%	$498K+1.4%	$491K+1.0%	$486K-5.6%	$515K-4.1%	$537K+1.1%	$531K+1.3%	$524K
Income Tax	$12K	$0	$0	$0+100.0%	-$170K	$0	$0	$0
Net Income	$58K+103.6%	-$1.6M+37.0%	-$2.6M-21.3%	-$2.1M+53.4%	-$4.6M-119.6%	-$2.1M-2179.1%	-$91K+97.3%	-$3.4M
EPS (Diluted)	$0.13	-$0.36+41.9%	-$0.62-21.6%	-$0.51+55.7%	-$1.15-125.5%	-$0.51-1600.0%	-$0.03	-$0.10

SSKN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SSKN quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$30.5M-12.6%	$34.9M-16.9%	$42.0M-19.6%	$52.3M+12.2%	$46.6M-0.4%	$46.8M-1.2%	$47.3M-0.3%	$47.5M+21.4%	$39.1M-9.4%	$43.2M-13.8%	$50.1M+149.5%	$20.1M+42.0%	$14.1M-18.2%	$17.3M-45.0%	$31.4M
Current Assets	$15.6M-6.0%	$16.6M+6.8%	$15.5M+3.3%	$15.1M-24.6%	$20.0M-19.6%	$24.8M+5.4%	$23.6M+1.5%	$23.2M+115.9%	$10.8M0.0%	$10.8M-10.2%	$12.0M-30.4%	$17.2M+66.2%	$10.4M+6.9%	$9.7M-66.7%	$29.1M
Cash & Equivalents	$7.9M+9.0%	$7.3M+7.0%	$6.8M+24.8%	$5.4M-56.8%	$12.6M+18.7%	$10.6M+30.4%	$8.1M-50.7%	$16.5M+305.2%	$4.1M+3.6%	$3.9M+18.9%	$3.3M-71.1%	$11.4M+202.2%	$3.8M-51.9%	$7.9M-71.9%	$28.0M
Inventory	$2.8M+25.3%	$2.2M-16.0%	$2.7M-13.6%	$3.1M-11.3%	$3.5M+1.3%	$3.4M+13.8%	$3.0M+8.3%	$2.8M-7.1%	$3.0M+6.8%	$2.8M-31.8%	$4.1M-21.7%	$5.3M-6.3%	$5.6M+733.0%	$676K	$0
Accounts Receivable	$4.1M-21.5%	$5.3M+18.3%	$4.4M-0.7%	$4.5M+30.2%	$3.4M+16.6%	$2.9M-32.9%	$4.4M+29.3%	$3.4M+8.0%	$3.1M-7.3%	$3.4M-16.7%	$4.1M+1749.1%	$220K+286.0%	$57K-68.3%	$180K	$0
Goodwill	$1.4M0.0%	$1.4M-78.1%	$6.5M-25.9%	$8.8M0.0%	$8.8M0.0%	$8.8M0.0%	$8.8M0.0%	$8.8M0.0%	$8.8M0.0%	$8.8M-1.4%	$8.9M	$0	N/A	N/A	N/A
Total Liabilities	$27.6M-7.8%	$30.0M+2.1%	$29.3M-3.7%	$30.4M+43.7%	$21.2M+1.4%	$20.9M+11.7%	$18.7M+15.0%	$16.3M-15.5%	$19.3M-31.6%	$28.2M-17.2%	$34.0M+336.1%	$7.8M+33.6%	$5.8M+77.1%	$3.3M+107.8%	$1.6M
Current Liabilities	$26.7M+99.6%	$13.4M+10.0%	$12.2M-9.3%	$13.4M+4.9%	$12.8M-32.0%	$18.8M+8.1%	$17.4M+102.4%	$8.6M-17.7%	$10.5M+15.8%	$9.0M+27.8%	$7.1M+223.7%	$2.2M-61.3%	$5.7M+87.2%	$3.0M+108.5%	$1.4M
Long-Term Debt	$0-100.0%	$15.2M+1.0%	$15.0M+101.2%	$7.5M+2.1%	$7.3M+597.0%	$1.1M	$0-100.0%	$7.1M-9.0%	$7.9M-19.5%	$9.8M-1.0%	$9.9M	$0	N/A	N/A	N/A
Total Equity	$2.9M-41.5%	$5.0M-60.8%	$12.7M-41.9%	$21.8M-14.1%	$25.4M-1.8%	$25.9M-9.6%	$28.7M-8.3%	$31.2M+57.2%	$19.9M+32.2%	$15.0M-6.5%	$16.1M+31.0%	$12.3M+48.0%	$8.3M-40.6%	$14.0M-53.1%	$29.8M
Retained Earnings	-$254.4M-2.5%	-$248.1M-4.2%	-$238.1M-4.8%	-$227.2M-2.5%	-$221.7M-1.2%	-$219.0M-2.1%	-$214.6M-1.8%	-$210.8M-3.3%	-$204.0M-11.8%	-$182.4M+12.0%	-$207.2M-13.7%	-$182.3M-8.4%	-$168.1M-18.2%	-$142.2M-19.0%	-$119.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$30.5M-0.6%	$30.7M+4.2%	$29.5M-10.7%	$33.0M-5.4%	$34.9M-11.3%	$39.4M+1.6%	$38.8M-1.2%	$39.2M
Current Assets	$15.6M+9.3%	$14.3M+3.6%	$13.8M-13.2%	$15.9M-4.3%	$16.6M+4.5%	$15.9M+14.9%	$13.8M+4.4%	$13.2M
Cash & Equivalents	$7.9M+11.8%	$7.1M+18.6%	$6.0M-8.4%	$6.5M-10.3%	$7.3M+2.8%	$7.1M+28.8%	$5.5M+4.7%	$5.2M
Inventory	$2.8M-8.0%	$3.1M-5.5%	$3.2M+21.7%	$2.7M+18.4%	$2.2M-18.1%	$2.7M+1.9%	$2.7M-0.1%	$2.7M
Accounts Receivable	$4.1M+17.6%	$3.5M-12.9%	$4.0M-19.7%	$5.0M-4.7%	$5.3M+18.2%	$4.4M+11.7%	$4.0M+9.6%	$3.6M
Goodwill	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M0.0%	$1.4M-74.9%	$5.7M0.0%	$5.7M0.0%	$5.7M
Total Liabilities	$27.6M-6.1%	$29.4M+1.5%	$29.0M-3.6%	$30.1M+0.3%	$30.0M-0.1%	$30.0M+2.5%	$29.3M-1.8%	$29.8M
Current Liabilities	$26.7M+77.9%	$15.0M+19.8%	$12.6M-7.7%	$13.6M+1.5%	$13.4M+1.8%	$13.2M+16.5%	$11.3M-3.9%	$11.8M
Long-Term Debt	$0-100.0%	$13.4M-12.0%	$15.3M+0.3%	$15.2M+0.3%	$15.2M+0.3%	$15.2M+0.3%	$15.1M+0.3%	$15.1M
Total Equity	$2.9M+121.3%	$1.3M+147.0%	$532K-82.1%	$3.0M-40.1%	$5.0M-47.1%	$9.4M-1.1%	$9.5M+0.8%	$9.4M
Retained Earnings	-$254.4M0.0%	-$254.5M-0.6%	-$252.8M-1.0%	-$250.3M-0.9%	-$248.1M-1.9%	-$243.6M-0.9%	-$241.5M0.0%	-$241.4M

SSKN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

SSKN quarterly cash flow statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$2.8M-1586.2%	$188K+136.2%	-$519K+43.8%	-$924K-161.3%	$1.5M-28.1%	$2.1M-6.0%	$2.2M-23.0%	$2.9M-30.0%	$4.1M+1185.7%	$322K+104.9%	-$6.6M+62.9%	-$17.7M+8.8%	-$19.4M-1.0%	-$19.2M-10.1%	-$17.5M
Capital Expenditures	$1.5M-10.3%	$1.6M-67.4%	$5.0M+34.3%	$3.7M+2.3%	$3.7M+69.2%	$2.2M+1777.4%	$115K	N/A	N/A	N/A	N/A	$0-100.0%	$5.2M-15.8%	$6.2M+5815.9%	$104K
Free Cash Flow	-$4.3M-194.3%	-$1.4M+73.9%	-$5.5M-18.8%	-$4.7M-117.2%	-$2.1M-3304.8%	-$63K-103.0%	$2.1M	N/A	N/A	N/A	N/A	-$17.7M+28.0%	-$24.6M+3.1%	-$25.4M-44.5%	-$17.6M
Investing Cash Flow	-$1.5M+10.3%	-$1.6M+67.4%	-$5.0M-14.9%	-$4.4M+38.7%	-$7.1M-230.1%	-$2.2M+22.6%	-$2.8M-56.4%	-$1.8M+18.6%	-$2.2M-152.8%	-$868K	N/A	N/A	N/A	-$6.2M-5816.2%	-$104K
Financing Cash Flow	$3.6M+85.9%	$1.9M-71.9%	$6.9M+1472.2%	-$500K-643.5%	$92K-96.4%	$2.5M+960.1%	-$296K-102.6%	$11.3M+727.1%	-$1.8M-254.5%	$1.2M	N/A	N/A	N/A	$5.2M-65.1%	$15.0M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$239K-273.4%	-$64K+96.7%	-$1.9M-252.9%	-$550K-178.2%	$703K+332.8%	-$302K-151.1%	$591K+173.5%	-$804K
Capital Expenditures	$312K-69.4%	$1.0M+1568.9%	-$61K-69.3%	$199K-60.5%	$504K+712.9%	$62K-82.0%	$345K-52.4%	$725K
Free Cash Flow	-$551K+49.1%	-$1.1M+46.0%	-$2.0M-167.3%	-$749K-476.4%	$199K+154.7%	-$364K-248.0%	$246K+116.1%	-$1.5M
Investing Cash Flow	-$312K+69.4%	-$1.0M-1768.9%	$61K+130.7%	-$199K+60.5%	-$504K-712.9%	-$62K+82.0%	-$345K+52.4%	-$725K
Financing Cash Flow	$1.4M-36.7%	$2.2M	$0	$0	$0-100.0%	$1.9M	$0+100.0%	-$18K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SSKN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

SSKN quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	58.3%+1.0pp	57.3%+1.9pp	55.3%-4.9pp	60.2%-6.0pp	66.2%+5.0pp	61.2%-3.0pp	64.2%+6.8pp	57.3%-1.7pp	59.1%+0.2pp	58.9%+33.0pp	25.8%	-439.3%	-709.9%	-633.5%	N/A
Operating Margin	-15.3%+12.3pp	-27.6%-1.8pp	-25.8%-12.9pp	-12.9%+1.8pp	-14.7%+3.0pp	-17.6%-8.1pp	-9.5%+1.7pp	-11.2%-5.6pp	-5.7%+6.0pp	-11.7%+77.4pp	-89.1%	-1816.6%	-4502.6%	-8160.9%	N/A
Net Margin	-20.4%+9.7pp	-30.0%+2.4pp	-32.5%-17.1pp	-15.3%-6.3pp	-9.0%+10.1pp	-19.1%-7.1pp	-12.0%+1.5pp	-13.5%+54.2pp	-67.7%-56.9pp	-10.9%	-134.9%	-1545.9%	-4841.0%	-8142.3%	N/A
Return on Equity	-215.3%-12.4pp	-202.9%-117.5pp	-85.4%-59.9pp	-25.4%-14.8pp	-10.7%+6.4pp	-17.0%-3.8pp	-13.2%-0.3pp	-12.9%+95.3pp	-108.2%-86.0pp	-22.2%+132.9pp	-155.1%-39.9pp	-115.2%+197.6pp	-312.8%-150.5pp	-162.2%-93.9pp	-68.4%
Return on Assets	-20.5%+8.4pp	-28.9%-3.1pp	-25.8%-15.2pp	-10.6%-4.8pp	-5.8%+3.6pp	-9.4%-1.4pp	-8.0%+0.5pp	-8.5%+46.5pp	-55.0%-47.3pp	-7.7%+42.1pp	-49.8%+20.7pp	-70.5%+113.1pp	-183.6%-52.3pp	-131.3%-66.4pp	-64.9%
Current Ratio	0.58-0.7x	1.240.0x	1.28+0.2x	1.12-0.4x	1.56+0.2x	1.320.0x	1.35-1.3x	2.69+1.7x	1.03-0.2x	1.19-0.5x	1.69-6.2x	7.87+6.0x	1.83-1.4x	3.21-16.9x	20.07
Debt-to-Equity	0.00-3.1x	3.06+1.9x	1.19+0.8x	0.34+0.1x	0.29+0.2x	0.040.0x	0.00-0.2x	0.23-0.2x	0.40-0.3x	0.650.0x	0.61+0.6x	0.00-0.7x	0.70+0.5x	0.24+0.2x	0.05
FCF Margin	-13.9%-9.6pp	-4.3%+12.3pp	-16.6%-3.7pp	-12.9%-5.7pp	-7.2%-6.9pp	-0.3%-7.0pp	6.7%	N/A	N/A	N/A	N/A	-1935.4%	-4589.7%	-9115.0%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	61.8%+1.4pp	60.4%+4.2pp	56.2%+2.6pp	53.5%-7.9pp	61.4%+1.3pp	60.1%+1.1pp	59.0%+13.4pp	45.6%
Operating Margin	5.3%+22.2pp	-16.9%+13.2pp	-30.1%-5.1pp	-25.0%+19.7pp	-44.8%-26.5pp	-18.2%-12.6pp	-5.7%+37.1pp	-42.8%
Net Margin	0.6%+24.0pp	-23.4%+10.2pp	-33.6%-2.5pp	-31.1%+16.4pp	-47.6%-24.0pp	-23.6%-22.5pp	-1.1%+48.8pp	-49.8%
Return on Equity	2.0%+125.4pp	-123.4%+360.6pp	-484.0%-412.8pp	-71.2%+20.4pp	-91.6%-69.6pp	-22.1%-21.1pp	-1.0%+34.7pp	-35.7%
Return on Assets	0.2%+5.5pp	-5.3%+3.5pp	-8.7%-2.3pp	-6.4%+6.6pp	-13.0%-7.8pp	-5.3%-5.0pp	-0.2%+8.3pp	-8.6%
Current Ratio	0.58-0.4x	0.95-0.1x	1.10-0.1x	1.17-0.1x	1.240.0x	1.210.0x	1.22+0.1x	1.13
Debt-to-Equity	0.00-10.2x	10.22-18.5x	28.70+23.6x	5.11+2.1x	3.06+1.4x	1.610.0x	1.590.0x	1.60
FCF Margin	-5.9%+9.7pp	-15.6%+10.5pp	-26.1%-15.1pp	-11.0%-13.1pp	2.1%+6.2pp	-4.1%-7.1pp	2.9%+25.6pp	-22.6%

Note: The current ratio is below 1.0 (0.58), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

HeartSciences Inc HSCS

$12.9M

Biomerica Inc BMRA

$5.5M

Pavmed PAVM

$42.2M

ReShape Lifesciences Inc. RSLS

$7.6M

Lifeward Ltd LFWD

$20.9M

Where Strata Skin Sciences Inc Ranks

Frequently Asked Questions

What is Strata Skin Sciences Inc's annual revenue?

Strata Skin Sciences Inc (SSKN) reported $30.7M in total revenue for fiscal year 2025. This represents a -8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Strata Skin Sciences Inc's revenue growing?

Strata Skin Sciences Inc (SSKN) revenue declined by 8.5% year-over-year, from $33.6M to $30.7M in fiscal year 2025.

Is Strata Skin Sciences Inc profitable?

No, Strata Skin Sciences Inc (SSKN) reported a net income of -$6.3M in fiscal year 2025, with a net profit margin of -20.4%.

What is Strata Skin Sciences Inc's EBITDA?

Strata Skin Sciences Inc (SSKN) had EBITDA of -$577K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Strata Skin Sciences Inc have?

As of fiscal year 2025, Strata Skin Sciences Inc (SSKN) had $7.9M in cash and equivalents against $0 in long-term debt.

What is Strata Skin Sciences Inc's gross margin?

Strata Skin Sciences Inc (SSKN) had a gross margin of 58.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Strata Skin Sciences Inc's operating margin?

Strata Skin Sciences Inc (SSKN) had an operating margin of -15.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Strata Skin Sciences Inc's net profit margin?

Strata Skin Sciences Inc (SSKN) had a net profit margin of -20.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Strata Skin Sciences Inc's return on equity (ROE)?

Strata Skin Sciences Inc (SSKN) has a return on equity of -215.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Strata Skin Sciences Inc's free cash flow?

Strata Skin Sciences Inc (SSKN) recorded an outflow of $4.3M in free cash flow during fiscal year 2025. This represents a -194.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Strata Skin Sciences Inc's operating cash flow?

Strata Skin Sciences Inc (SSKN) recorded an outflow of $2.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Strata Skin Sciences Inc's total assets?

Strata Skin Sciences Inc (SSKN) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Strata Skin Sciences Inc's capital expenditures?

Strata Skin Sciences Inc (SSKN) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Strata Skin Sciences Inc spend on research and development?

Strata Skin Sciences Inc (SSKN) invested $421K in research and development during fiscal year 2025.

How many shares does Strata Skin Sciences Inc have outstanding?

Strata Skin Sciences Inc (SSKN) had 6M shares outstanding as of fiscal year 2025.

What is Strata Skin Sciences Inc's current ratio?

Strata Skin Sciences Inc (SSKN) had a current ratio of 0.58 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Strata Skin Sciences Inc's debt-to-equity ratio?

Strata Skin Sciences Inc (SSKN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Strata Skin Sciences Inc's return on assets (ROA)?

Strata Skin Sciences Inc (SSKN) had a return on assets of -20.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Strata Skin Sciences Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Strata Skin Sciences Inc (SSKN) held $7.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $2.8M over that year. Dividing the one by the other, the reported balance equals about 34 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Strata Skin Sciences Inc's Piotroski F-Score?

Strata Skin Sciences Inc (SSKN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Strata Skin Sciences Inc's earnings high quality?

Strata Skin Sciences Inc (SSKN) reported a net loss of $6.3M while operations used $2.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Strata Skin Sciences Inc cover its interest payments?

Strata Skin Sciences Inc (SSKN) reported an operating loss of $4.7M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.